Literature DB >> 28660376

Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization.

Pantelis Tsirkinidis1, Evangelos Terpos2, Georgios Boutsikas3, Athanasios Papatheodorou4, Konstantinos Anargyrou3, Eleni Lalou5, Aglaia Dimitrakopoulou6, Christina Kalpadakis7, Konstantinos Konstantopoulos5, Marina Siakantaris8, Panayiotis Panayiotidis9, Gerassimos Pangalis10, Marie-Christine Kyrtsonis9, Theodoros Vassilakopoulos5, Maria K Angelopoulou11.   

Abstract

Hematopoietic stem cell (HSC) mobilization involves cleavage of ligands between HSC and niche components. However, there are scarce data regarding the role of bone cells in human HSC mobilization. We studied biochemical markers of bone metabolism and angiogenic cytokines during HSC mobilization in 46 patients' sera with lymphoma and multiple myeloma, by ELISA. Significant changes between pre-mobilization and collection samples were found: (1) Bone alkaline phosphatase (BALP) increased, indicating augmentation of bone formation; (2) Receptor activator of Nf-κB ligand/osteoprotegerin ratio (RANKL/OPG) increased, showing osteoclastic differentiation and survival; however, there was no evidence of increased osteoclastic activity; and (3) Angiopoietin-1/Angiopoietin-2 ratio (ANGP-1/ANGP-2) decreased, consistent with vessel destabilization. Poor mobilizers had significantly higher carboxy-terminal telopeptide of collagen type I (CTX) and lower ANGP-1 at pre-mobilization samples, compared to good ones. CTX, amino-terminal telopeptide of collagen type I (NTX) and ANGP-1 pre-mobilization levels correlated significantly with circulating CD34+ peak cell counts. Our results indicate that bone formation and vessel destabilization are the two major events during human HSC mobilization. Osteoblasts seem to be the orchestrating cells, while osteoclasts are stimulated but not fully active. Moreover, ANGP-1, CTX and NTX may serve as predictors of poor mobilization.

Entities:  

Keywords:  Angiopoietins; Bone cells; Bone markers; Hematopoietic stem cells; Mobilization

Mesh:

Substances:

Year:  2017        PMID: 28660376     DOI: 10.1007/s00774-017-0853-4

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  41 in total

Review 1.  Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.

Authors:  L C Hofbauer
Journal:  Eur J Endocrinol       Date:  1999-09       Impact factor: 6.664

2.  Angiopoietins in haematopoietic stem cell mobilisation in patients with haematological malignancies.

Authors:  Anna Szmigielska-Kaplon; Anna Krawczynska; Magdalena Czemerska; Agnieszka Pluta; Barbara Cebula-Obrzut; Katarzyna Szmigielska; Konrad Stępka; Piotr Smolewski; Tadeusz Robak; Agnieszka Wierzbowska
Journal:  Blood Transfus       Date:  2014-09-12       Impact factor: 3.443

3.  Comparison of analytical performance and biological variability of three bone resorption assays.

Authors:  H S Ju; S Leung; B Brown; M A Stringer; S Leigh; C Scherrer; K Shepard; D Jenkins; J Knudsen; R Cannon
Journal:  Clin Chem       Date:  1997-09       Impact factor: 8.327

Review 4.  Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis.

Authors:  Magda Kucia; Ryan Reca; Katarzyna Miekus; Jens Wanzeck; Wojtek Wojakowski; Anna Janowska-Wieczorek; Janina Ratajczak; Mariusz Z Ratajczak
Journal:  Stem Cells       Date:  2005-05-11       Impact factor: 6.277

Review 5.  Mobilization of hematopoietic stem/progenitor cells: general principles and molecular mechanisms.

Authors:  Halvard Bonig; Thalia Papayannopoulou
Journal:  Methods Mol Biol       Date:  2012

Review 6.  Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.

Authors:  Robert Coleman; Janet Brown; Evangelos Terpos; Allan Lipton; Matthew R Smith; Richard Cook; Pierre Major
Journal:  Cancer Treat Rev       Date:  2008-06-24       Impact factor: 12.111

Review 7.  New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target?

Authors:  Steeve Kwan Tat; Jean-Pierre Pelletier; Carmen Ruiz Velasco; Marc Padrines; Johanne Martel-Pelletier
Journal:  Keio J Med       Date:  2009-03

Review 8.  The role of Dickkopf-1 in bone development, homeostasis, and disease.

Authors:  Joseph J Pinzone; Brett M Hall; Nanda K Thudi; Martin Vonau; Ya-Wei Qiang; Thomas J Rosol; John D Shaughnessy
Journal:  Blood       Date:  2008-08-07       Impact factor: 22.113

9.  Intercellular adhesion molecule-1 inhibits osteogenic differentiation of mesenchymal stem cells and impairs bio-scaffold-mediated bone regeneration in vivo.

Authors:  Fen-Fen Xu; Heng Zhu; Xi-Mei Li; Fei Yang; Ji-De Chen; Bo Tang; Hong-Guang Sun; Ya-Nan Chu; Rong-Xiu Zheng; Yuan-Lin Liu; Li-Sheng Wang; Yi Zhang
Journal:  Tissue Eng Part A       Date:  2014-06-05       Impact factor: 3.845

Review 10.  The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in.

Authors:  Armin Ehninger; Andreas Trumpp
Journal:  J Exp Med       Date:  2011-03-14       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.